Evidence map›Paper›PMID 42467361›Full record

ArticleMedScience2026

CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.

Xiao Liu, Guangzhao Yang, Haozhe Qin, Qi Zhang, Zhihao Guan, Maorong Zhu, Cheng Zou, Yawen Wang, Yuxin Wu, Duo Yu and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiao Liu *Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Guangzhao Yang *Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Haozhe Qin *Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Qi Zhang *Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Zhihao GuanDepartment of Neurosurgery, the 987 Hospital of PLA Joint Logistic Support Force, Baoji, 721000, China.
Maorong ZhuState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Cheng ZouState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Yawen WangAir Force Medical Center of PLA, The Fourth Military Medical University, Beijing, 100042, China.
Yuxin WuState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Duo YuDepartment of Neurosurgery, General Hospital of Central Theater Command, Wuhan, 430000, China.
Dan ZhengState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Juan LiDepartment of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.
Jintao GuState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China.
Zhengcong CaoState Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, 710032, China. caozhengcong0928@163.com.
Zhengmin LiDepartment of Anesthesiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710032, China. lizhengminmazui@163.com.
Yalong HeDepartment of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China. heyl.fmmu@hotmail.com.
Wei LinDepartment of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China. linwei@fmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM), the most aggressive central nervous system (CNS) malignancy, currently lacks curative therapeutic options. While immunotherapy has revolutionized treatment for many cancers, GBM remains refractory to immune-based interventions due to the absence of effective immunotherapeutic targets. Here, through CRISPR screening, we identify Niemann-Pick C1-like 1 (NPC1L1) as a previously unrecognized key driver of GBM progression. Mechanistically, NPC1L1 modulates cholesterol metabolism to concurrently enhance tumor cell stemness and suppress CD8

Indexed as

Central Nervous System NeoplasmsCholesterolGene Expression Regulation, NeoplasticGlioblastomaMembrane Transport ProteinsAnimalsAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCD8-Positive T-LymphocytesClustered Regularly Interspaced Short Palindromic RepeatsDisease Models, AnimalDisease ProgressionEzetimibeHumansLymphocyte ActivationMiceAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterolEzetimibeMembrane Transport ProteinsNPC1L1 protein, humancholesterolglioblastomaimmunotherapyNPC1L1tumor microenvironment

Identifiers

PMID42467361

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.